@article{1484630,
      author = {Shegokar, Ranjita,},
      url = {http://library.usi.edu/record/1484630},
      title = {Exploring drug delivery to the peritoneum /},
      abstract = {The Peritoneal cavity (PC) is the key metastatic site  for intra-abdominal malignancies (e.g., GI tract and  rectal cancer). PC sites can be used to target several  other diseases where lymphatic drug delivery is desired  without dumping large amounts of the drug. Until recently,  it was thought that treatment with curative intent was  impossible but that was challenged  by the introduction of cytoreductive surgery (CRS),  heated intraperitoneal chemotherapy (HIPEC), and PIPAC  (pressurized intraperitoneal aerosol chemotherapy).  Recently, a growing number of preclinical and clinical  studies advocate intraperitoneal (IP) chemotherapy as an  alternative post-operative therapy for cancer. Although  their effectiveness has been proven both experimentally and  clinically, there is still little understanding of the role  of drug delivery systems in targeting drugs in  the intraperitoneal (IP) cavity. There are two main  challenges posed to such therapies 1) the complexity of IP  cavity and 2) the drug transport dynamics e.g., the  residence time of small molecular weight drugs, the fate  of delivery systems (both nano and micro), etc.  The present book is a link between pharmaceutical  scientists (drug formulators), clinicians, and  toxicologists. This book also provides a new perspective  to researchers to divert or guide their research in an  optimal way. Exploring Drug Delivery to the Peritoneum  serves as a platform for upcoming technologies especially  in the medical devices sector to face up and show  potential in delivering drugs to IP cavity. It is a chance  for commercial partners like insurance companies and  the pharma industry to explore the old administration  route in a new way. .},
      doi = {https://doi.org/10.1007/978-3-031-31694-4},
      recid = {1484630},
      pages = {1 online resource (x, 242 pages) :},
}